Article
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.
Nature genetics - 1 Aug 2015
Eleveld Thomas F, Oldridge Derek A, Bernard Virginie, Koster Jan, Colmet Daage Léo, Diskin Sharon J, Schild Linda, Bentahar Nadia Bessoltane, Bellini Angela, Chicard Mathieu, Lapouble Eve, Combaret Valérie, Legoix-Né Patricia, Michon Jean, Pugh Trevor J, Hart Lori S, Rader JulieAnn, Attiyeh Edward F, Wei Jun S, Zhang Shile, Naranjo Arlene, Gastier-Foster Julie M, Hogarty Michael D, Asgharzadeh Shahab, Smith Malcolm A, Guidry Auvil Jaime M, Watkins Thomas B K, Zwijnenburg Danny A, Ebus Marli E, van Sluis Peter, Hakkert Anne, van Wezel Esther, van der Schoot C Ellen, Westerhout Ellen M, Schulte Johannes H, Tytgat Godelieve A, Dolman M Emmy M, Janoueix-Lerosey Isabelle, Gerhard Daniela S, Caron Huib N, Delattre Olivier, Khan Javed, Versteeg Rogier, Schleiermacher Gudrun, Molenaar Jan J, Maris John M
Abstract excerpt
The majority of patients with neuroblastoma have tumors that initially respond to chemotherapy, but a large proportion will experience therapy-resistant relapses. The molecular basis of this aggressive phenotype is unknown. Whole-genome sequencing of 23 paired diagnostic and relapse neuroblastomas showed clonal evolution from the diagnostic tumor, with a median of 29 somatic mutations unique to the relapse...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.